非小细胞肺癌的向治疗:机制和临床试验
Le Yu1, Ruoyi Yang1, Zeng Long2
1Sichuan Cancer Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
向疗法,包括单克隆抗体和氨酸激酶抑制剂,显著改善了非小细胞肺癌 (NSCLC) 治疗. 这篇综述涵盖了它们的机制,当前状态,抵抗力和未来的挑战.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 肺癌仍然是全球癌症死亡的主要原因之一.
- 传统化疗对晚期非小细胞肺癌 (NSCLC) 的疗效有限.
- 针对性治疗的最新进展改善了NSCLC患者的预后.
研究的目的:
- 审查NSCLC针对性治疗的机制和当前状态.
- 讨论克服针对性疗法所获得的耐药性的策略.
- 为应对NSCLC向治疗领域的现有挑战.
主要方法:
- 对针对NSCLC的向疗法的现有文献的审查.
- 对单克隆抗体 (mAbs),抗体-药物联合体 (ADC) 和氨酸激酶抑制剂 (TKI) 的作用机制的分析.
- 检查NSCLC中的EGFR和ALK等遗传点.
主要成果:
- 包括mAbs,ADC和TKIs在内的向疗法为NSCLC患者提供了更好的结果.
- 了解EGFR和ALK等特定突变对于有效的向治疗至关重要.
- 获得性耐药性仍然是一个重大挑战,需要进一步研究克服它.
结论:
- 向治疗代表了NSCLC治疗的范式转变,提高了患者的生存率和生活质量.
- 对抗性机制和新型治疗策略的持续研究是必不可少的.
- 基于分子分析的个性化医疗方法是优化NSCLC管理的关键.
更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Clinical Trials: Overview
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Clinical Trials
There are four phases in a clinical trial. A phase one...
